Mobile

A Study to Assess the Pharmacokinetics (absorption, distribution, metabolisation, excretion), Pharmacodynamics (biochemical and physiological effects of the drug), Efficacy, Safety, Tolerability, and ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-004742-18

A Study to Assess the Pharmacokinetics (absorption, distribution, metabolisation, excretion), Pharmacodynamics (biochemical and physiological effects of the drug), Efficacy, Safety, Tolerability, and Immunogenicity (Immune response) of a Single, Subcutaneous Dose of 100μg/kg XM22 in 21 Children with Ewing Family of Tumors or Rhabdomyosarcoma

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the study is to assess the pharmacokinetics (PK) of a single subcutaneous (SC) injection of XM22, 100 μg/kg body weight (BW), in children with Ewing family of tumors or rhabdomyosarcoma.

Critère d'inclusion

  • Children with Ewing Family of Tumors or Rhabdomyosarcoma receiving cytotoxic Chemotherapy for malignancy inducing neutropenia

Liens